This article is mentioned in:

Introduction

Clinically, acute ischemic cerebrovascular disease is very common with high morbidity, mortality and disability (1). Cerebral ischemia can trigger nerve cell damage (1). The fundamental measures for preventing ischemic injury are to recover the blood supply as soon as possible (2). With the recovery of blood perfusion to the ischemic area after continuing cerebral ischemia for a certain period of time, the original cells at the ischemic area cannot recover (2). Thus, this aggravates ischemic injury. This phenomenon is known as cerebral ischemia/reperfusion injury (CIRI) (3). The pathogenesis of CIRI is more complex than that of pure hypoxic-ischemic brain damage and is associated with nerve cell apoptosis, the breakdown of high energy phosphate compounds, lipid peroxidation, inflammatory reactions, the toxic effects of excitatory amino acids, calcium overload, the functions of nitric oxide (NO) and endothelial cell dysfunction (4–6). However, the specific mechanisms responsible for the pathogenesis of CIRI have not yet been fully elucidated.

Sirtuin 1 (SIRT1) is a type of histone deacetylase dependent on NAD+, which is the highest factor in homologous genes of mammals in silent information regulator SIR2 (7). Studies have confirmed that SIRT1 is extensively expressed in tissues and organs and is associated with metabolic syndrome, tumors and neurodegenerative diseases (8–10). A previous study demonstrated that icariin exerted neuroprotective effects through the induction of SIRT1, and that these effects were reversed by the use of a SIRT1 inhibitor (11). Moreover, SIRT1 can regulate many transcription factors and receptors, such as hypermethylated in cancer 1 (HIC1), C-terminal-binding protein (CtBP), p53, forkhead box O3 (FOXO3A) and E2F transcription factor 1 (E2F1) (9,11,12). The hippocampus is a key structure of learning and memory in the brain. The expression of SIRT1 in the brain is the material basis for its participation in regulating cognitive functions (13). SIRT1 plays a role in neuronal differentiation (13). It has also been shown that SIRT1 participates in the dendronization of neuronal dentritic cells (11). The overexpression of SIRT1 in nurtured hippocampal neurons enhances the dendronization of dendrites (14).

During the later decades of an individual's life, the morbidity and death rates triggered by cerebral ischemia are relatively high. Owing to delayed neuronal death (DND), despite survival after an attack, nervous system sequelae, such as motor dysfunction, and language and cognitive deficits may occur (15). It has been proven that apoptosis is closely associated with DND. Some apoptosis-related genes have also been found. The tumor suppressor gene, p53, has been found to participate in the DND of brain neurons following ischemia. It has dual functions in cerebral ischemia (16). When DNA is damaged, p53 causes cell cycle arrest, which helps the repair of DNA. When DNA cannot be restored, it can induce cell apoptosis (17).

During the process of ischemia/reperfusion, many genes undergo alterations, resulting in the inhibition of some proteins, while the expression of other harmful proteins is significantly upregulated (18). As important components in genetic expression, the levels and functions of mRNAs are regulated by several factors. Studies have found that microRNAs participate in various biological process, such as embryogenesis, proliferation, differentiation and cell death (19,20). Thus, it has been predicted that microRNAs regulate genec expression in over a third of animals. In diseases of the nervous system, the abnormal expression of microRNAs is associated with the dysfunction of synaptogenesis and synaptic reorganization, degenerative diseases, tumors and epilepsy (18,20). A recent study indicated that microRNAs (microRNA-107) participate in the development of CIRI (21). In the present study, therefore, we wished to determine whether SIRT1 exerts neuroprotective effects by attenuating CIRI and explored the mechanisms involved.

Materials and methods

Animals, model of CIRI and drug treatment

Sprague-Dawley male rats (n=56, weighing, 230–260 g) were purchased from Founder Animal's Pharmaceutcal Co., Ltd. (Cangzhou, China) and kept (22±1°C, 55±5% humidity) on a 12 h light/dark cycle with ad libitum access to food and water. All experimental procedures were approved by the Committee of Cangzhou Central Hospital in accordance with the NIH Guide for the Care and Use of Laboratory Animals. The rats were anesthetized with chloral hydrate [300 mg/kg, intraperitoneal (i.p.) injection]. LPS (1 mg/ml; Sigma, St. Louis, MO USA) was injected into the corpus callosum in order to induce CIRI. After 1 day, focal cerebral ischemia was induced by right-sided endovascular middle cerebral artery occlusion. The suture was pulled back and the rats were allowed to recover after 2 h of ischemia. Firstly, 32 rats were randomly assigned into 4 groups as follows: i) the sham-operated (control, n=8) group; ii) the vehicle group (CIRI model, n=8); iii) the group treated with 5 mg/kg of sc-222315 (SIRT1 activator 3, n=8; chemical structure shown in Fig. 1A); and iv) the group treated with 10 mg/kg group of sc-222315 (n=8). A total of 16 rats were treated with SIRT1 activator 3 for 48 h by intraperitoneal injection. Subsequently, 24 rats were randomly assigned into 3 groups as follows: i) the sham-operated (control, n=8) group; ii) the vehicle group (CIRI model, n=8); and the group treated with 10 mg/kg of sirtinol (S7942; SIRT1 inhibitor, n=8; chemical structure shown in Fig. 1B). A total of 8 rats were treated with sirtinol for 48 h by intraperitoneal injection. The rats were then anesthetized with chloral hydrate (300 mg/kg, by intraperitoneal injection) and sacrificed by decollation. The brains were immediately removed for determining the infarct volume, and the brain tissue samples were washed with PBS and stored at -80 °C until use.

Figure 1 Chemical structure of SIRT1 activator 3 and sirtinol. The chemical structure of (A) SIRT1 activator 3 and (B) sirtinol.

Measurement of infarct volume and neurological deficit score

The brain tissue samples were cut into coronal slices of 2 mm for determining the infarct volume using 2% triphenyltetrazolium chloride (TTC; Sigma). The integrating 6 selected sections were used to calculate the infarct volume, and the corrected infarct volumes were calculated to compensate for brain edema. The neurological deficit score was analyzed based on the following criteria and five-point scoring system: no neurological injury symptoms was given a score of 0; inability to entirely extend the front jaw on the heterolateral side was given a score of 1; rotation while crawling and falling to the heterolateral side was given a score of 2; inability to walk without assistance was given a score of 3; unconsciousness was given a score of 4.

Measurement of inflammation and caspase-3 activity

Brain samples were homogenized in 50 mM Tris buffer and were then subjected to centrifugation at 12,000 × g for 10 min at 4°C for determining the activity of tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-10, and caspase-3 in the rat brains using ELISA kits in accordance with the manufacturer's instructions (Elabscience Biology Co., Ltd., Wuhan, China).

Western blot analysis

The brain samples were homogenized in 50 mM Tris buffer, and the protein concentration in the supernatant was determined using the Micro BCA protein assay kit with bovine serum albumin as the standard (Pierce, Rockford, IL, USA) following centrifugation at 12,000 × g at 4°C for 10 min. Total protein (50 μg) was subjected to 10–12% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). The membranes were incubated with 5% non-fat dry milk in Tween-20 (0.1%)-containing TBS for 1 h, followed by incubation with primary antibodies against cyclooxygenase (COX)-2 (sc-7951), inducible NO synthase (iNOS; sc-650), p53 (sc-47698) and β-actin (sc-47778) (all from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at 4°C overnight. The membranes were washed with TBST and then incubated with anti-mouse or anti-rabbit secondary antibody (sc-2354 or sc-2768; Santa Cruz Biotechnology, Inc.) and examined using the ECL kit (Amersham, Piscataway, NJ, USA).

Real-time PCR

Total RNA was extracted from the brain samples using TRIzol reagent according to the manufacturer's instructions (Sigma). The gene expression of microRNA-22 was detected by TaqMan MicroRNA assays using looped-primer reverse transcription (RT)-PCR. The conditions for PCR were as follows: at 95°C for 10 min; at 95°C for 30 sec and 60°C for 30 sec followed by 40 cycles. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. The sequences of the primers used were as follows: GAPDH sense, 5′-GAAGGTGAAGGTCGGAGTC-3′ and antisense, 5′-GAAGATGGTGATGGGATTTC-3′; and microRNA-22 sense, 5′-AACTCGAGCGAGTCCTCTCCTAGGACTA-3′ and antisense, 5′-TTGCGGCCGCACACAAAGCTTAAATATG-3′.

Statistical analysis

Data are expressed as the means ± SD and analyzed for statistical significance using one-way ANOVA, followed by Scheffe's test for multiple comparisons. A value of P<0.05 was considered to indicate a statistically significant difference.

Results

SIRT1 decreases the infarct volume and improves the neurological deficit score in a rat model of CIRI

Initially, we examined the effects of SIRT1 on the infarct volume and neurological deficit score in rats with CIRI. As shown in Fig. 2, the rats with CIRI exhibited a significant increase in infarct volume and the neurological deficit score, compared with the rats in the sham-operated group. However, treatment with 10 mg/kg of SIRT1 activator 3 significantly attenuated the CIRI-induced increase int he infarct volume and neurological deficit score in the rats (Fig. 2).

Figure 2 SIRT1 decreases the infarct volume and neurological deficit score in rats with cerebral ischemia reperfusion-induced injury (CIRI). SIRT1 decreases the (A) infarct volume and (B) neurological deficit score in rats with CIRI. Sham, sham-operated group; vehicle, CIRI model rat group; 5 mg/kg, group treated with 5 mg/kg of SIRT1 activator 3; 10 mg/kg, group treated with 10 mg/kg of SIRT1 activator 3. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

SIRT1 attenuates inflammation in a rat model of CIRI

We then examined the neuroprotective effects of SIRT1 on inflammatory reactions in our rat model of CIRI. The activity of TNF-α and II-6 was significantly enhanced, and that of IL-10 was significantly inhibited following CIRI, compared with the sham-operated group (Fig. 3). However, treatment with 10 mg/kg of SIRT1 activator 3 significantly suppressed the activity of TNF-α and II-6, and increased that of IL-10 in the rats with CIRI (Fig. 3).

Figure 3 SIRT1 attenuates inflammation in rats with cerebral ischemia reperfusion-induced injury (CIRI). SIRT1 decreased the activity of (A) tumor necrosis factor-α (TNF-α), (B) interleukin (II)-6 and (C) IL-10 in rats with CIRI. Sham, sham-operated group; vehicle, CIRI model rat group; 5 mg/kg, group treated with 5 mg/kg of SIRT1 activator 3; 10 mg/kg, group treated with 10 mg/kg of SIRT1 activator 3. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

SIRT1 decreases COX-2 protein expression in a rat model of CIRI

Furthermore, to clarify the regulatory mechanisms of SIRT1 in rats with CIRI, we first examined COX-2 protein expression in our rat model of CIRI. As shown in Fig. 4, CIRI significantly increased the protein expression of COX-2 in the rats with CIRI, compared with those in the sham-operated group. The induction of COX-2 protein expression following CIRI was significantly attenuated by treatment with 10 mg/kg of SIRT1 activator 3 in the rats with CIRI (Fig. 4).

Figure 4 SIRT1 decreases COX-2 protein expression in rats with cerebral ischemia reperfusion-induced injury (CIRI). SIRT1 decreased COX-2 protein expression, as shown by (A) western blot analysis and (B) statistical analysis of COX-2 protein expression in rats with CIRI. Sham, sham-operated group; vehicle, CIRI model rat group; 5 mg/kg, group treated with 5 mg/kg of SIRT1 activator 3; 10 mg/kg, group treated with 10 mg/kg of SIRT1 activator 3. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

SIRT1 decreases iNOS protein expression in a rat model of CIRI

The neuroprotective effects of SIRT1 against CIRI may be modulated by various mechanisms, such as the iNOS pathway. Compared with the sham-operated group, CIRI significantly increased iNOS protein expression in the rats with CIRI (Fig. 5). By contrast, treatment with 10 mg/kg of SIRT1 activator 3 significantly decreased iNOS protein expression in the rats with CIRI (Fig. 5).

Figure 5 SIRT1 decreases iNOS protein expression in rats with cerebral ischemia reperfusion-induced injury (CIRI). SIRT1 decreased iNOS protein expression, as shown by (A) western blot analysis and (B) statistical analysis of iNOS protein expression in rats with CIRI. Sham, sham-operated group; vehicle, CIRI model rat group; 5 mg/kg, group treated with 5 mg/kg of SIRT1 activator 3; 10 mg/kg, group treated with 10 mg/kg of SIRT1 activator 3. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

SIRT1 decreases caspase-3 activity in a rat model of CIRI

To examine the role of caspase-3 activity in the effects of SIRT1 on CIRI, caspase-3 activity was measured using an ELISA kit. Indeed, there was a significant increase in caspase-3 activity in the rats with CIRI, compared with those in the sham-operated group (Fig. 6). By contrast, treatment with 10 mg/kg of SIRT1 activator 3 significantly decreased caspase-3 activity in the rts with CIRI (Fig. 6).

Figure 6 SIRT1 decrases caspase-3 activity in rats with cerebral ischemia reperfusion-induced injury (CIRI). SIRT1 decreased caspase-3 activity as shown by ELISA in rats with CIRI. Sham, sham-operated group; vehicle, CIRI model rat group; 5 mg/kg, group treated with 5 mg/kg of SIRT1 activator 3; 10 mg/kg, group treated with 10 mg/kg of SIRT1 activator 3. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

SIRT1 decreases p53 protein expression in a rat model of CIRI

To examine the expression profile of p53 protein in the brain tissue samples of rats with CIRI, we performed western blot analysis. The results revealed that the protein expression of p53 was upregulated following CIRI, although this did not reach statistical significance (Fig. 7). Furthermore, treatment with 10 mg/kg of SIRT1 activator 3 significantly decreased p53 expression in the rats with CIRI (Fig. 7).

Figure 7 SIRT1 decreases p53 protein expression in rats with cerebral ischemia reperfusion-induced injury (CIRI). SIRT1 decreased p53 protein expression, as shown by (A) western blot analysis and (B) statistical analysis of p53 protein expression in rats with CIRI. Sham, sham-operated group; vehicle, CIRI model rat group; 5 mg/kg, group treated with 5 mg/kg of SIRT1 activator 3; 10 mg/kg, group treated with 10 mg/kg of SIRT1 activator 3. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

SIRT1 increases microRNA-22 expression in a rat model of CIRI

We examined the correlation between the effects of SIRT1 and microRNA-22 expression in our rat model of CIRI. The expression of microRNA-22 in the rats with CIRI was significantly inhibited, compared with that in the sham-operated group (Fig. 8). Moreover, the decrease in microRNA-22 expression in the rats with CIRI was reversed by treatment with 10 mg/kg of SIRT1 activator 3 (Fig. 8).

Figure 8 SIRT1 increases microRNA-22 expression in rats with cerebral ischemia reperfusion-induced injury (CIRI). Sham, sham group; vehicle, CIRI model rat group; 5 mg/kg, group treated with 5 mg/kg of SIRT1 activator 3; 10 mg/kg, group treated with 10 mg/kg of SIRT1 activator 3. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

Downregulation of SIRT1 increases the infarct volume and neurological deficit score in a rat model of CIRI

We then investigated the effects of the downregulation of SIRT1 on infarct volume and neurological deficit score in our rat model of CIRI. As shown by our results, the downregulation of SIRT1 (by treatment with 10 mg/kg of sirtinol) significantly increased the infarct volume and neurological deficit score in the rats with CIRI, compared with the CIRI model group (Fig. 9).

Figure 9 Downregulation of SIRT1 by sirtinol increases the infarct volume and neurological deficit score in rats with cerebral ischemia reperfusion-induced injury (CIRI). Downregulation of SIRT1 increased (A) the infarct volume and (B) the neurological deficit score in rats with CIRI. Sham, sham group; vehicle, CIRI model rat group. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

Downregulation of SIRT1 enhances inflammation in a rat mdoel of CIRI

Subsequently, to further examine the effects of SIRT1 in CIRI brain tissue, we examined the expression of inflammation-related markers in rats with CIRI. The downregulation of SIRT1 (10 mg/kg of sirtinol) significantly increased the activity of TNF-α and II-6, and inhibited IL-10 activity in the rats with CIRI, compared with the CIRI model group (Fig. 10).

Figure 10 Downregulation of SIRT1 by sirtinol increases inflammation in rats with cerebral ischemia reperfusion-induced injury (CIRI). Downregulation of SIRT1 increased the activity of (A) tumor necrosis factor-α (TNF-α), (B) interleukin (II)-6 and (C) IL-10 in rats with CIRI. Sham, sham group; vehicle, CIRI model rat group; ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

Downregulation of SIRT1 increases COX-2 protein expression in a rat model of CIRI

We then examined COX-2 protein expression following the downregulation of SIRT1 by western blot analysis. The downregulation of SIRT1 (by treatment with 10 mg/kg of sirtinol) significantly increased the protein expression of COX-2 in the rats with CIRI, compared with the CIRI model group (Fig. 11).

Figure 11 Downregulation of SIRT1 by sirtinol increases COX-2 protein expression in rats with cerebral ischemia reperfusion-induced injury (CIRI). Downregulation of SIRT1 increased COX-2 protein expression, as shown by (A) western blot analysis and (B) statistical analysis of COX-2 protein expression in rats with CIRI. Sham, sham group; vehicle, CIRI model rat group. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

Downregulation of SIRT1 increases iNOS protein expression in a rat model of CIRI

We then further examined the effects of the downregulation of SIRT1 on iNOS protein expression in the rats with CIRI. As shown in Fig. 12, the downregulation of SIRT1 (by treatment with 10 mg/kg of sirtinol) significantly enhanced the protein expression of iNOS in the rats with CIRI, compared with the CIRI model group.

Figure 12 Downregulation of SIRT1 by sirtinol increases iNOS protein expression in rats with cerebral ischemia reperfusion-induced injury (CIRI). Downregulation of SIRT1 increased iNOS protein expression, as shown by (A) western blot analysis and (B) statistical analysis of iNOS protein expression in rats with CIRI. Sham, sham group; vehicle, CIRI model rat group. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

Downregulation of SIRT1 increases caspase-3 activity in a rat model of CIRI

We then sought to determine whether SIRT1 regulates caspase-3 activity using a SIRT1 inhibitor. According to the results of ELISA, the downregulation of SIRT1 (by treatment with 10 mg/kg of sirtinol) significantly increased caspase-3 activity in the rats with CIRI, compared with the CIRI model group (Fig. 13).

Figure 13 Downregulation of SIRT1 by sirtinol increases caspase-3 activity in rats with cerebral ischemia reperfusion-induced injury (CIRI). Downregulation of SIRT1 increased caspase-3 activity in rats with CIRI. Sham, sham group; vehicle, CIRI model rat group. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

Downregulation of SIRT1 increases p53 protein expression in a rat model of CIRI

As p53 signaling is activated with the upregulation of SIRT1, we also examined p53 protein expression in the rats with CIRI following treatment with 10 mg/kg of sirtinol. As shown in Fig. 14, treatment with 10 mg/kg of sirtinol significantly increased p53 protein expression in the rats with CIRI, compared with the CIRI model group.

Figure 14 Downregulation of SIRT1 by sirtinol increases p53 protein expression in rats with cerebral ischemia reperfusion-induced injury (CIRI). Downregulation of SIRT1 increased p53 protein expression, as shown by (A) western blot analysis and (B) statistical analysis of p53 protein expression in rats with CIRI. Sham, sham group; vehicle, CIRI model rat group. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

Downregulation of SIRT1 decreased microRNA-22 expression in a rat model of CIRI

We also performed real-time PCR to examine the effects of the downregulation of SIRT1 on microRNA-22 expression in our rat model of CIRI. Indeed, treatment with 10 mg/kg of sirtinol significantly inhibited microRNA-22 expression in the rats with CIRI, compared with the CIRI model group (Fig. 15).

Figure 15 Downregulation of SIRT1 by sirtinol decreases microRNA-22 expression in rats with cerebral ischemia reperfusion-induced injury (CIRI). Sham, sham group; vehicle, CIRI model rat group. ##p<0.01 compared with sham group; **p<0.01 compared with vehicle group.

Discussion

During the process of embryonic development, SIRT1 is highly expressed in the brain, spinal cord and dorsal root ganglion (11). In adult brains, SIRT1 is highly expressed in the cortex, hippocampus and epencephalon, while it has a lower expression in aged neurons (14). At present, there is evidence to indicate that SIRT1 plays versatile roles in the central nervous system, such as neurogenesis and neuroprotection. The increase in the gene expression of SIRT1 can reduce β-amyloidotic enzyme deposition in rats models of ischemic stroke-induced brain injury and facilitate neuronal survival (13). In addition, SIRT1 plays an important role in the prevention of axonal degenerative disease. SIRT1 can decide the fate of neuronal precursor cells (22). In our study, we found that SIRT1 exerted neuroprotective effects by decreasing the infarct volume and neurological deficit score in a rat model of CIRI. Collectively, our results suggested that SIRT1 may prove to be an important therapeutic target for the treatment of CIRI. Ding et al also suggested that SIRT1 protected against myocardial ischemia-reperfusion injury in diabetic rats (23).

p53 genes are the key regulating point of cellular signaling pathways under a number of pathological conditions and complete adaptive responses by interacting with target genes (24). p53 and its downstream genes play an essential role in cerebral ischemic cell apoptosis (25). Downstream genes of p53 have two functions, the regulation of the cell cycle and the regulation of cell apoptosis, such as the Bcl-2 family (16). In this study, SIRT1 exerted neuroprotective effects by attenuating p53 protein expression in rats with CIRI. These data suggest that the decreased expression of SIRT1 may contribute to the increased expression of p53 protein in rats with CIRI. Sin et al suggested that the effects of resveratrol on muscle injury were mediated through SIRT1, p53 and caspase-3 in skeletal muscle (26).

With neurotransmitter functions, NO is an important signaling and effector molecule, which extensively participates in physiological and pathological events (27). In the process of CIRI, according to different periods of ischemia and reperfusion, cell types and procedures of NO production, NO can exert dual functions of injury or protection (28). It has been suggested that during CIRI, NOS is the key determinant of whether NO has dual functions (29). At an advanced stage of CIRI, NO generated by iNOS can intensify the toxicity of glutamic acid and result in delayed neuronal damage (27). Particularly, the close integration of iNOS and calmodulin further aggravates DND (30,31). In this study, we found that SIRT1 exerted neuroprotective effects by suppressing iNOS protein expression in rats with CIRI.

COX-2 is a key enzyme in the metabolic pathway of arachidonic acid (AA) (32). Also known as prostaglandin G/H synthetase, COX is the catalyzing enzyme of the metabolic transformation of prostaglandins (PGs) and hromboxane (TX) from AA (24). COX exists in tissues in the forms of two subtypes. COX-1 is structural and has certain activities in normal conditions with the basic functions of maintaining physiological processes and the stability of the inner environment (33). COX-2 is inducible and is rarely expressed in normal tissues, while it is highly expressed in tissues during inflammation (34). Many inflammation simulating factors, such as LPS, IL-1, TNF, serum, epidermal growth factor-α and platelet-activating factor can induce the genetic expression of COX-2 and trigger an increase in the levels of PGE2, PGI2 and PGE1 at inflammatory sites (33). COX and its metabolites can aggravate CIRI at the vasculature, blood-brain barrier and neurons (33). The present study clearly demonstrated that SIRT1 exerted neuroprotective effects by suppressing COX-2 protein expression in rats with CIRI. Gano et al reported that the SIRT1 activator, SRT1720, reversed vascular endothelial dysfunction through COX-2 and inflammation in aged mice (35).

Neuro-inflammation during CIRI is key factor giving rise to breakdown, encephaledema and nerve injury. Various measures to relieve the inflammatory response can significantly protect the blood-brain barrier and prevent encephaledema and nerve injury. It has been found that as the dominant ingredient of astragalus, formononetin can markedly reduce the expression of iNOS, IL-1β and TNF-α, and decrease the activity of matrix metalloproteinases (MMPs) and the permeability of the blood-brain barrier, as well as improve nerve function deficit and exert marked neuroprotective effects (36). Our results demonstrated that SIRT1 exerted neuroprotective effect by suppressing the expression of inflammation-related markers in rats with CIRI.

A fair amount of evidence has indicated that apoptosis is strongly linked with nerve cell damage caused by cerebral hypoxia-ischemia (37). Following CIRI, DND may occur at the ischemia-sensitive area and is closely related with molecular mechanisms in the apoptotic process (38). Following focal brain ischemia reperfusion, apoptotic pathways are activated at the ischemia penumbra, resulting in neuronal damage (39). There are three major pathways of cell apoptosis, namely the extrinsic, intrinsic and endoplasmic reticulum (40). As a type of proteolytic enzymes playing key roles, the family of caspases runs through the beginning to the end of the three pathways. As an important family member in the caspase family, caspase-3 plays an essential role in launching, and executing cell apoptosis and cell death (40,41). Our present in vivo results demonstrated that SIRT1 exerted neuroprotective effect by inhibiting caspase-3 activity in rats with CIRI. Sin et al suggested that the effects of resveratrol on muscle injury were mediated through SIRT1, p53 and caspase-3 in skeletal muscle (26).

MicroRNAs are widely involved in the regulation of nervous system growth and development, as well as in the maintenance of various biological functions (42). MicroRNAs have been found to be expressed in cerebral tissues, and to play a role in the growth and differentiation of cerebral tissues (42). As a complex organ with various cell types, cerebral tissues have different cellular components and synaptic connections at different sites (43). Neurons differentiate from progenitor cells. Studies have confirmed that microRNAs promote the differentiation of progenitor cells into certain nerve cells by regulating the expression of target genes and promote differentiated nerve cells maintain innate features (20). In cerebral tissues, cells of different types have individual expression profiles (44). In the present study, we also demonstrated that SIRT1 exerted neuroprotective effects by increasing microRNA-22 expression in rats with CIRI. Zhang et al demonstrated that microRNA-22 functions as a tumor suppressor in renal cell carcinoma through SIRT1 (45).

In conclusion, in the present study, we demonstrated that SIRT1 exerted neuroprotective effects by decreasing the infarct volume and neurological deficit score, suppressing inflammation, decreasing COX-2 and iNOS expression, and inhibiting caspase-3 activity in a rat model of CIRI through the p53/microRNA-22 pathway. Our results open a new line of investigation aimed to determine the neuroprotective effects of SIRT1, which may prove to be an important therapeutic target in CIRI.

References